JAK2 and myeloproliferative neoplasm: Patients with MPNs are known to be at an elevated risk of thrombosis, but the mechanism for MPN-related coagulation activation is not yet fully characterized [16]; there is evidence that JAK2-mutated ECs may contribute to the MPN pro-thrombotic state [45, 51].